Dual vs triple anti-thrombotic therapy for post-PCI patients with atrial fibrillation

Dual vs triple anti-thrombotic therapy for post-PCI patients with atrial fibrillation: Scope of the problem and key challenges

Learning Objectives

  • Discuss and debate the four major trials in the DOAC space for post PCI patients with atrial fibrillation in light of international guidelines
  • Review the differences in the study designs and aspirin cut-offs and the implications on the data
  • Discuss and analyse the role of aspirin in the treatment of anti-thrombotic post PCI for patients with Atrial Fibrillation and ACS
  • Analyse and debate the impact on patient care

 


Programme Outline
  • PART 1: Scope of the problem and key challengesJan SteffelJur ten BergStefan H Hohnloser
  • PART 2: Evolution of the data – the trials and the differencesJan SteffelJur ten BergStefan H Hohnloser
  • PART 3: Practical implementation and current guidelinesJan SteffelJur ten BergStefan H Hohnloser
This video series was funded by an unrestricted educational service from Boehringer Ingelheim.

Dual vs triple anti-thrombotic therapy for post-PCI patients with atrial fibrillation: Evolution of the data – the trials and the differences